These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12017321)

  • 21. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma.
    Liu W; Liu Y; Zhu J; Wright E; Ding I; Rodgers GP
    Clin Cancer Res; 2008 Feb; 14(4):1041-9. PubMed ID: 18281536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon.
    Foley EF; Gaffey MJ; Frierson HF
    Arch Pathol Lab Med; 1998 Oct; 122(10):912-4. PubMed ID: 9786353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromogranin A expression in familial versus sporadic prostate cancer.
    Sciarra A; Monti S; Gentile V; Salciccia S; Autran Gòmez AM; Pannunzi LP; Di Silverio F
    Urology; 2005 Nov; 66(5):1010-4. PubMed ID: 16286114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine differentiation in ovarian mucinous tumors.
    Jiang C; Tan Y; Li E; Zhang D
    Chin Med J (Engl); 2000 Jan; 113(1):70-4. PubMed ID: 11775215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of chromogranin A mRNA in small cell carcinoma of the lung.
    Hamid Q; Corrin B; Sheppard MN; Huttner WB; Polak JM
    J Pathol; 1991 Apr; 163(4):293-7. PubMed ID: 1851827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogranin A expression correlates with tumour cell type and prognosis in signet ring cell carcinoma of the stomach.
    Fujiyoshi Y; Eimoto T
    Histopathology; 2008 Feb; 52(3):305-13. PubMed ID: 18269581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
    Tokunaga M; Yasuda M; Osamura RY; Itoh J; Mukai M; Shima M; Usui Y; Masuda A; Miyakita H; Terachi T
    Oncol Rep; 2005 Jun; 13(6):1081-7. PubMed ID: 15870925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant potential regarding mucin phenotypes and endocrine cell differentiation in gastric adenocarcinoma.
    Naritomi K; Futami K; Arima S; Iwashita A
    Anticancer Res; 2003; 23(6a):4411-22. PubMed ID: 14666728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
    Howe MC; Chapman A; Kerr K; Dougal M; Anderson H; Hasleton PS
    Histopathology; 2005 Feb; 46(2):195-201. PubMed ID: 15693892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma.
    Chung YC; Chang KJ; Yang CC; Lai MT; Hsu CP; Hsueh SF; Peng CC; Fu HH; Chang YF; Yang SD
    Cancer; 2002 Nov; 95(9):1840-7. PubMed ID: 12404276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.